Impact of General Factors on Glioma Immunotherapy

키워드

참고문헌 (122)

1. Louis DN, "The 2021 WHO classification of tumors of the central nervous system : a summary", Neuro Oncol, 23, pp.1231~1251 (2021)
2. Lapointe S, "Primary brain tumours in adults", Lancet, 392, pp.432~446 (2018)
3. Sanmamed MF, "A paradigm shift in cancer immunotherapy : from enhancement to normalization", Cell, 175, pp.313~326 (2018)
4. Wang H, "Immunotherapy for malignant glioma : current status and future directions", Trends Pharmacol Sci, 41, pp.123~138 (2020)
5. Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
6. Topalian SL, "Immune checkpoint blockade : a common denominator approach to cancer therapy", Cancer Cell, 27, pp.450~461 (2015)
7. Anderson AC, "Lag-3, Tim-3, and TIGIT : coinhibitory receptors with specialized functions in immune regulation", Immunity, 44, pp.989~1004 (2016)
8. Katz JB, "Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape", Immunol Rev, 222, pp.206~221 (2008)
9. Moran AE, "The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy", Curr Opin Immunol, 25, pp.230~237 (2013)
10. Luksik AS, "The role of immune checkpoint inhibition in the treatment of brain tumors", Neurotherapeutics, 14, pp.1049~1065 (2017)
11. Rudd CE, "CD28 and CTLA-4 coreceptor expression and signal transduction", Immunol Rev, 229, pp.12~26 (2009)
12. Qureshi OS, "Trans-endocytosis of CD80 and CD86 : a molecular basis for the cell-extrinsic function of CTLA-4", Science, 332, pp.600~603 (2011)
13. Topalian SL, "Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy", Nat Rev Cancer, 16, pp.275~287 (2016)
14. Selby MJ, "Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells", Cancer Immunol Res, 1, pp.32~42 (2013)
15. Wing K, "CTLA-4 control over Foxp3+ regulatory T cell function", Science, 322, pp.271~275 (2008)
16. BerghoffAS, "Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma", Neuro Oncol, 17, pp.1064~1075 (2015)
17. Bloch O, "Gliomas promote immunosuppression through induction of B7-H1expression in tumor-associated macrophages", Clin Cancer Res, 19, pp.3165~3175 (2013)
18. Dubinski D, "CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloidderived suppressor cells in glioblastoma patients", Neuro Oncol, 18, pp.807~818 (2016)
19. Wintterle S, "Expression of the B7-related molecule B7-H1by glioma cells : a potential mechanism of immune paralysis", Cancer Res, 63, pp.7462~7467 (2003)
20. Francisco LM, "PD-L1 regulates the development, maintenance, and function of induced regulatory T cells", J Exp Med, 206, pp.3015~3029 (2009)
21. DiDomenico J, "The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma", Oncoimmunology, 7, pp.e1448329~ (2018)
22. Wong KK, "Advances in therapeutic cancer vaccines", Adv Immunol, 130, pp.191~249 (2016)
23. Yang J, "Targeting EGFRvIII for glioblastoma multiforme", Cancer Lett, 403, pp.224~230 (2017)
24. Waitkus MS, "Isocitrate dehydrogenase mutations in gliomas", Neuro Oncol, 18, pp.16~26 (2016)
25. Weller M, "Vaccine-based immunotherapeutic approaches to gliomas and beyond", Nat Rev Neurol, 13, pp.363~374 (2017)
26. Liu R, "Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors", Cancer Immunol Immunother, 59, pp.183~193 (2010)
27. Sampson JH, "Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblasto-ma", J Clin Oncol, 28, pp.4722~4729 (2010)
28. Srinivasan VM, "Tumor vaccines for malignant gliomas", Neurotherapeutics, 14, pp.345~357 (2017)
29. Jeanbart L, "Engineering opportunities in cancer immunotherapy", Proc Natl Acad Sci U S A, 112, pp.14467~14472 (2015)
30. Liau LM, "First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma", J Transl Med, 16, pp.142~ (2018)
31. Phuphanich S, "Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma", Cancer Immunol Immunother, 62, pp.125~135 (2013)
32. Wen PY, "A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma", Clin Cancer Res, 25, pp.5799~5807 (2019)
33. Fesnak AD, "Engineered T cells : the promise and challenges of cancer immunotherapy", Nat Rev Cancer, 16, pp.566~581 (2016)
34. Fousek K, "The evolution of T-cell therapies for solid malignancies", Clin Cancer Res, 21, pp.3384~3392 (2015)
35. Brown CE, "Regression of glioblastoma after chimeric antigen receptor T-cell therapy", N Engl J Med, 375, pp.2561~2569 (2016)
36. Hegde M, "Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape", J Clin Invest, 126, pp.3036~3052 (2016)
37. Bielamowicz K, "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma", Neuro Oncol, 20, pp.506~518 (2018)
38. Johnson LA, "Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma", Sci Transl Med, 7, pp.275~ (2015)
39. Yi Z, "Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma", Mol Ther Methods Clin Dev, 9, pp.70~80 (2018)
40. Jiang H, "Selective targeting of glioblastoma with EGFRvIII", EGFR bitargeted chimeric antigen receptor T cell, 2018, pp.6, 1314~1326
41. Roh TH, "Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area : a retrospective study", J Neurosurg, 132, pp.895~901 (2019)
42. 홍제범, "Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas", Cancer Research and Treatment, 52(4), pp.1041~1049 (2020), 대한암학회[DOI]
43. Sanai N, "Surgical oncology for gliomas : the state of the art", Nat Rev Clin Oncol, 15, pp.112~125 (2018)
44. Weller M, "Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma(ACT IV) : a randomised, double-blind, international phase 3 trial", Lancet Oncol, 18, pp.1373~1385 (2017)
45. Lakin N, "Current advances in checkpoint inhibitors : lessons from non-central nervous system cancers and potential for glioblastoma", Front Oncol, 7, pp.141~ (2017)
46. Twyman-Saint Victor C, "Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer", Nature, 520, pp.373~377 (2015)
47. Weichselbaum RR, "Radiotherapy and immunotherapy : a beneficial liaison?", Nat Rev Clin Oncol, 14, pp.365~379 (2017)
48. Burnette B, "Radiation as an immune modulator", Semin Radiat Oncol, 23, pp.273~280 (2013)
49. Wang Y, "The reciprocity between radiotherapy and cancer immunotherapy", Clin Cancer Res, 25, pp.1709~1717 (2019)
50. Weiss T, "NKG2Dbased CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma", Cancer Res, 78, pp.1031~1043 (2018)
51. Song X, "Radiotherapy upregulates programmed death ligand-1 through the pathways downstream of epidermal growth factor receptor in glioma", EBioMedicine, 28, pp.105~113 (2018)
52. Derer A, "Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells", Front Immunol, 7, pp.610~ (2016)
53. Zeng J, "Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas", Int J Radiat Oncol Biol Phys, 86, pp.343~349 (2013)
54. Belcaid Z, "Focal radiation therapy combined with 4-1BB activation and CTLA4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model", PLoS One, 9, pp.e101764~ (2014)
55. Grossman SA, "Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide", Clin Cancer Res, 17, pp.5473~5480 (2011)
56. Hughes MA, "Primary brain tumors treated with steroids and radiotherapy : low CD4 counts and risk of infection", Int J Radiat Oncol Biol Phys, 62, pp.1423~1426 (2005)
57. Piotrowski AF, "Systemic depletion of lymphocytes following focal radiation to the brain in a murine model", Oncoimmunology, 7, pp.e1445951~ (2018)
58. Kleinberg L, "Radiotherapy, lymphopenia, and host immune capacity in glioblastoma : a potentially actionable toxicity associated with reduced efficacy of radiotherapy", Neurosurgery, 85, pp.441~453 (2019)
59. Karachi A, "Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition", Neuro Oncol, 21, pp.730~741 (2019)
60. Lim M, "Current state of immunotherapy for glioblastoma", Nat Rev Clin Oncol, 15, pp.422~442 (2018)
61. Hotchkiss KM, "Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor", J Neurooncol, 151, pp.51~62 (2021)
62. Akasaki Y, "Phase I", II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma, 2016, pp.65, 1499~1509
63. Daniel P, "Temozolomide induced hypermutation in glioma : evolutionary mechanisms and therapeutic opportunities", Front Oncol, 9, pp.41~ (2019)
64. Park J, "Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma", Oncoimmunology, 8, pp.e1525243~ (2019)
65. Mathios D, "Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM", Sci Transl Med, 8, pp.370~ (2016)
66. Suryadevara CM, "Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblasto-ma", Oncoimmunology, 7, pp.e1434464~ (2018)
67. Sampson JH, "Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIIIexpressing tumor cells in patients with glioblastoma", Neuro Oncol, 13, pp.324~333 (2011)
68. Di Tacchio M, "Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF", Cancer Immunol Res, 7, pp.1910~1927 (2019)
69. Voron T, "VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors", J Exp Med, 212, pp.139~148 (2015)
70. Alfaro C, "Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes", Br J Cancer, 100, pp.1111~1119 (2009)
71. Missiaen R, "The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer", Semin Cancer Biol, 52, pp.107~116 (2018)
72. Malo CS, "Immunomodulation mediated by anti-angiogenic therapy improves CD8 T cell immunity against experimental glioma", Front Oncol, 8, pp.320~ (2018)
73. Friedman HS, "Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma", J Clin Oncol, 27, pp.4733~4740 (2009)
74. Kreisl TN, "Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma", J Clin Oncol, 27, pp.740~745 (2009)
75. SchiffD, "The siren song of bevacizumab : swan song or clarion call?", Neuro Oncol, 20, pp.147~148 (2018)
76. Tamura R, "Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab", Cancer Sci, 110, pp.499~508 (2019)
77. Thomas AA, "Immune modulation associated with vascular endothelial growth factor(VEGF)blockade in patients with glioblastoma", Cancer Immunol Immunother, 66, pp.379~389 (2017)
78. Carter T, "Ipilimumab and bevacizumab in glioblastoma", Clin Oncol(R Coll Radiol), 28, pp.622~626 (2016)
79. Boydell E, "Exploratory study of the effect of ima950", poly-iclc vaccination on response to bevacizumab in relapsing high-grade glioma patients, 2019, pp.11, 464~
80. Stupp R, "Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma : a randomized clinical trial", JAMA, 318, pp.2306~2316 (2017)
81. Silginer M, "Biological activity of tumortreating fields in preclinical glioma models", Cell Death Dis, 8, pp.e2753~ (2017)
82. Trusheim J, "A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma", CNS Oncol, 6, pp.29~43 (2017)
83. Lee YJ, "Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields(TTFields)treatment", Sci Rep, 10, pp.12272~ (2020)
84. Ghiaseddin AP, "Tumor treating fields in the management of patients with malignant gliomas", Curr Treat Options Oncol, 21, pp.76~ (2020)
85. Voloshin T, "Tumor-treating fields(TTFields)induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy", Cancer Immunol Immunother, 69, pp.1191~1204 (2020)
86. Pitter KL, "Corticosteroids compromise survival in glioblastoma", Brain, 139, pp.1458~1471 (2016)
87. Giles AJ, "Dexamethasone-induced immunosuppression : mechanisms and implications for immunotherapy", J Immunother Cancer, 6, pp.51~ (2018)
88. Maxwell R, "Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system", Oncoimmunology, 7, pp.e1500108~ (2018)
89. Keskin DB, "Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial", Nature, 565, pp.234~239 (2019)
90. Brown CE, "Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma", Mol Ther, 26, pp.31~44 (2018)
91. Wick W, "Treatment of glioblastoma in adults", Ther Adv Neurol Disord, 11, pp.1756286418790452~ (2018)
92. Stoll EA, "The impact of age on oncogenic potential : tumor-initiating cells and the brain microenvironment", Aging Cell, 12, pp.733~741 (2013)
93. Santoro A, "Innate immunity and cellular senescence : the good and the bad in the developmental and aged brain", J Leukoc Biol, 103, pp.509~524 (2018)
94. Pawelec G, "Age and immunity : what is"immunosenescence"?", Exp Gerontol, 105, pp.4~9 (2018)
95. Lee JH, "Human glioblastoma arises from subventricular zone cells with low-level driver mutations", Nature, 560, pp.243~247 (2018)
96. Alexandrov LB, "Clock-like mutational processes in human somatic cells", Nat Genet, 47, pp.1402~1407 (2015)
97. Pawelec G, "Does patient age influence anti-cancer immunity?", Semin Immunopathol, 41, pp.125~131 (2019)
98. Jan CI, "Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme", Front Immunol, 9, pp.727~ (2018)
99. Kugel CH 3rd, "Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations", Clin Cancer Res, 24, pp.5347~5356 (2018)
100. Ferrara R, "Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients : does age really matter?", Cancer Treat Rev, 60, pp.60~68 (2017)
101. Tian M, "Impact of gender on the survival of patients with glioblastoma", Biosci Rep, 38, pp.BSR20180752~ (2018)
102. Ostrom QT, "CBTRUS statistical report : primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014", Neuro Oncol, 19, pp.v1~v88 (2017)
103. Yang W, "Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data", Sci Transl Med, 11, pp.eaao5253~ (2019)
104. Capone I, "Sexual dimorphism of immune responses : a new perspective in cancer immunotherapy", Front Immunol, 9, pp.552~ (2018)
105. Lin PY, "B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses", J Immunol, 185, pp.2747~2753 (2010)
106. Wang Z, "Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade", Nat Med, 25, pp.141~151 (2019)
107. Murphy KA, "Cutting edge : elevated leptin during diet-induced obesity reduces the efficacy of tumor immunotherapy", J Immunol, 201, pp.1837~1841 (2018)
108. Dai S, "Chronic stress promotes cancer development", Front Oncol, 10, pp.1492~ (2020)
109. Zhang L, "Chronic stress-induced immune dysregulation in cancer : implications for initiation, progression, metastasis, and treatment", Am J Cancer Res, 10, pp.1294~1307 (2020)
110. Jun-fang Qin, "Adrenergic receptor β2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment", BMB Reports, 48(5), pp.295~300 (2015), 생화학분자생물학회
111. Yang H, "Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity", Nat Med, 25, pp.1428~1441 (2019)
112. Kokolus KM, "Stressful presentations : mild cold stress in laboratory mice influences phenotype of dendritic cells in naïve and tumorbearing mice", Front Immunol, 5, pp.23~ (2014)
113. Bucsek MJ, "β-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy", Cancer Res, 77, pp.5639~5651 (2017)
114. Rhee SH, "Principles and clinical implications of the brain-gut-enteric microbiota axis", Nat Rev Gastroenterol Hepatol, 6, pp.306~314 (2009)
115. Roy S, "Microbiota : a key orchestrator of cancer therapy", Nat Rev Cancer, 17, pp.271~285 (2017)
116. Blander JM, "Regulation of inflammation by microbiota interactions with the host", Nat Immunol, 18, pp.851~860 (2017)
117. Honda K, "The microbiota in adaptive immune homeostasis and disease", Nature, 535, pp.75~84 (2016)
118. Sivan A, "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy", Science, 350, pp.1084~1089 (2015)
119. Vétizou M, "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", Science, 350, pp.1079~1084 (2015)
120. Gopalakrishnan V, "Gut microbiome modulates response to antiPD-1 immunotherapy in melanoma patients", Science, 359, pp.97~103 (2018)
121. Routy B, "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors", Science, 359, pp.91~97 (2018)
122. Zitvogel L, "The microbiome in cancer immunotherapy : diagnostic tools and therapeutic strategies", Science, 359, pp.1366~1370 (2018)

관련 논문AI추천